Neuroblastoma pp 191-203 | Cite as

Neonatal Neuroblastoma

  • Dominique PlantazEmail author
  • Claire Freycon


Neonatal neuroblastoma accounts for less than 5% of all cases of neuroblastoma and presents a favorable prognosis with most patients being stratified into low or very low risk of recurrence and some in intermediate and very rarely in high risk. Owing to the unique potential for spontaneous regression of this tumor type, all groups have sought to reduce therapy burden given to neonates and use a watch-and-wait approach for many of these patients, particularly for those with prenatal detection of an adrenal tumor. Ongoing studies also seek to reduce therapy for some intermediate-risk patients to lessen exposure to surgical intervention and chemotherapy risk in this very fragile population. In this review, we discuss the epidemiology, clinical presentation, staging, biology, and treatment for neonates with neuroblastoma.


Neuroblastoma Newborn Antenatal diagnosis Regression 


  1. 1.
    Georgakis MK, Dessypris N, Baka M, Moschovi M, Papadakis V, Polychronopoulou S, Kourti M, Hatzipantelis E, Stiakaki E, Dana H, Bouka E, Antunes L, Bastos J, Coza D, Demetriou A, Agius D, Eser S, Gheorghiu R, Sekerija M, Trojanowski M, Zagar T, Zborovskaya A, Ryzhov A, Tragiannidis A, Panagopoulou P, Steliarova-Foucher E, Petridou ET. Neuroblastoma among children in Southern and Eastern European cancer registries: variations in incidence and temporal trends compared to US. Int J Cancer. 2018;142:1985.CrossRefGoogle Scholar
  2. 2.
    Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, Dimitrova N, Jakab Z, Kaatsch P, Lacour B, Mallone S, Marcos-Gragera R, Minicozzi P, Sánchez-Pérez MJ, Sant M, Santaquilani M, Stiller C, Tavilla A, Trama A, Visser O, Peris-Bonet R, EUROCARE Working Group. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5--a population-based study. Lancet Oncol. 2014;15:35–47.CrossRefGoogle Scholar
  3. 3.
    Koh V, Soh SY, Chan MY, Tan AM. Neuroblastoma in children under 12 months in singapore-15-year experience and outcomes from KKH. Fetal Pediatr Pathol. 2015;34:155–61.CrossRefGoogle Scholar
  4. 4.
    Gigliotti AR, Di Cataldo A, Sorrentino S, Parodi S, Rizzo A, Buffa P, Granata C, Sementa AR, Fagnani AM, Provenzi M, Prete A, D’Ippolito C, Clerico A, Castellano A, Tonini GP, Conte M, Garaventa A, De Bernardi B. Neuroblastoma in the newborn. A study of the Italian Neuroblastoma Registry. Eur J Cancer. 2009;45:3220–7.CrossRefGoogle Scholar
  5. 5.
    Zhou Y, Li K, Zheng S, Chen L. Retrospective study of neuroblastoma in Chinese neonates from 1994 to 2011: an evaluation of diagnosis, treatments, and prognosis: a 10-year retrospective study of neonatal neuroblastoma. J Cancer Res Clin Oncol. 2014;140:83–7.CrossRefGoogle Scholar
  6. 6.
    Evans AE, D’Angio GJ, Propert K, Anderson J, Hann HW. Prognostic factor in neuroblastoma. Cancer. 1987;59:1853–9.CrossRefGoogle Scholar
  7. 7.
    Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985;313(18):1111–6.CrossRefGoogle Scholar
  8. 8.
    Goto S, Umehara S, Gerbing RB, Stram DO, Brodeur GM, Seeger RC, Lukens JN, Matthay KK, Shimada H. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children’s Cancer Group. Cancer. 2001;92:2699–708.CrossRefGoogle Scholar
  9. 9.
    London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, Thorner P, Brodeur G, Maris JM, Reynolds CP, Cohn SL. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J Clin Oncol. 2005;23:6459–65.CrossRefGoogle Scholar
  10. 10.
    Michalowski MB, Rubie H, Michon J, Montamat S, Bergeron C, Coze C, Perel Y, Valteau-Couanet D, Guitard J, Guys JM, Piolat C, Munzer C. Plantaz D; Neonatal localized neuroblastoma: 52 cases treated from 1990 to 1999. Arch Pediatr. 2004;11:782–8.CrossRefGoogle Scholar
  11. 11.
    Acharya S, Jayabose S, Kogan SJ, Tugal O, Beneck D, Leslie D, Slim M. Prenatally diagnosed neuroblastoma. Cancer. 1997;80:304–10.CrossRefGoogle Scholar
  12. 12.
    Sauvat F, Sarnacki S, Brisse H, Medioni J, Rubie H, Aigrain Y, Gauthier F, Audry G, Helardot P, Landais P, Michon J, Hartmann O, Nihoul-Fékété C. Outcome of suprarenal localized masses diagnosed during the perinatal period: a retrospective multicenter study. Cancer. 2002;94:2474–80.CrossRefGoogle Scholar
  13. 13.
    Voûte PA Jr, Wadman SK, van Putten WJ. Congenital neuroblastoma. Symptoms in the mother during pregnancy. Clin Pediatr. 1970;9:206–7.CrossRefGoogle Scholar
  14. 14.
    Newton ER, Louis F, Dalton ME, Feingold M. Fetal neuroblastoma and catecholamine-induced maternal hypertension. Obstet Gynecol. 1985;65:49S–52S.PubMedGoogle Scholar
  15. 15.
    Delahaye S, Doz F, Sonigo P, Saada J, Mitanchez D, Sarnacki S, Benachi A. Prenatal diagnosis of dumbbell neuroblastoma. Ultrasound Obstet Gynecol. 2008;3:92–5.CrossRefGoogle Scholar
  16. 16.
    Dhir S, Wheeler K. Neonatal neuroblastoma. Early Hum Dev. 2010;86:601–5.CrossRefGoogle Scholar
  17. 17.
    Fisher JP, Tweddle DA. Neonatal neuroblastoma. Semin Fetal Neonatal Med. 2012;17:207–15.CrossRefGoogle Scholar
  18. 18.
    Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–77.CrossRefGoogle Scholar
  19. 19.
    Interiano RB, Davidoff AM. Current Management of Neonatal Neuroblastoma. Curr Pediatr Rev. 2015;11:179–87.CrossRefGoogle Scholar
  20. 20.
    Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, Giammarile F, Schmidt M, Shulkin BL, Matthay KK, Lewington VJ, Sarnacki S, Hero B, Kaneko M, London WB, Pearson AD, Cohn SL, Monclair T. International Neuroblastoma Risk Group Project. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011;261:243–57.CrossRefGoogle Scholar
  21. 21.
    Schilling FH, Oberrauch W, Schanz F, Treuner J. Evaluation of a rapid and reliable method for mass screening for neuroblastoma in onfants. Prog Clin Biol Res. 1991;366:579–83.PubMedGoogle Scholar
  22. 22.
    Schilling FH, Spix C, Berthold F, Erttmann R, Fehse N, Hero B, Klein G, Sander J, Schwarz K, Treuner J, Zorn U, Michaelis J. Neuroblastoma screening at one year of age. N Engl J Med. 2002;346:1047–53.CrossRefGoogle Scholar
  23. 23.
    Shinagawa T, Kitamura T, Katanoda K, Matsuda T, Ito Y, Sobue T. The incidence and mortality rates of neuroblastoma cases before and after the cessation of the mass screening program in Japan: a descriptive study. Int J Cancer. 2017;140:618–25.CrossRefGoogle Scholar
  24. 24.
    Beckwith JB, Perrin EV. In situ neuroblastoma: a contribution to the natural history of neural crest tumors. Am J Pathol. 1963;43:1089–104.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Nuchtern JG, London WB, Barnewolt CE, Naranjo A, McGrady PW, Geiger JD, Diller L, Schmidt ML, Maris JM, Cohn SL, Shamberger RC. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children’s Oncology Group study. Ann Surg. 2012;256:573–80.CrossRefGoogle Scholar
  26. 26.
    Hero B, Simon T, Spitz R, Ernestus K, Gnekow AK, Scheel-Walter HG, Schwabe D, Schilling FH, Benz-Bohm G, Berthold F. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol. 2008;26:1504–10.CrossRefGoogle Scholar
  27. 27.
    Schleiermacher G, Michon J, Ribeiro A, Pierron G, Mosseri V, Rubie H, Munzer C, Bénard J, Auger N, Combaret V, Janoueix-Lerosey I, Pearson A, Tweddle DA, Bown N, Gerrard M, Wheeler K, Noguera R, Villamon E, Cañete A, Castel V, Marques B, de Lacerda A, Tonini GP, Mazzocco K, Defferrari R, de Bernardi B, di Cataldo A, van Roy N, Brichard B, Ladenstein R, Ambros I, Ambros P, Beiske K, Delattre O, Couturier J. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). Br J Cancer. 2011;105:1940–8.CrossRefGoogle Scholar
  28. 28.
    Chicard M, Boyault S, Colmet Daage L, Richer W, Gentien D, Pierron G, Lapouble E, Bellini A, Clement N, Iacono I, Bréjon S, Carrere M, Reyes C, Hocking T, Bernard V, Peuchmaur M, Corradini N, Faure-Conter C, Coze C, Plantaz D, Defachelles AS, Thebaud E, Gambart M, Millot F, Valteau-Couanet D, Michon J, Puisieux A, Delattre O, Combaret V, Schleiermacher G. Genomic copy number profiling using circulating free tumor DNA highlights heterogeneity in neuroblastoma. Clin Cancer Res. 2016;22:5564–73.CrossRefGoogle Scholar
  29. 29.
    Brodeur GM. Spontaneous regression of neuroblastoma. Cell Tissue Res. 2018;372:277. Scholar
  30. 30.
    De Bernardi B, Mosseri V, Rubie H, Castel V, Foot A, Ladenstein R, Laureys G, Beck-Popovic M, de Lacerda AF, Pearson AD, De Kraker J, Ambros PF, de Rycke Y, Conte M, Bruzzi P, Michon J, SIOP Europe Neuroblastoma Group. Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. Br J Cancer. 2008;99:1027–33.CrossRefGoogle Scholar
  31. 31.
    Ikeda H, Suzuki N, Takahashi A, Kuroiwa M, Nagashima K, Tsuchida Y, Matsuyama S. Surgical treatment of neuroblastomas in infants under 12 months of age. J Pediatr Surg. 1998;33:1246–50.CrossRefGoogle Scholar
  32. 32.
    Cecchetto G, Mosseri V, De Bernardi B, Helardot P, Monclair T, Costa E, Horcher E, Neuenschwander S, Tomà P, Rizzo A, Michon J, Holmes K. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol. 2005;23:8483–9.CrossRefGoogle Scholar
  33. 33.
    Rubie H, De Bernardi B, Gerrard M, Canete A, Ladenstein R, Couturier J, Ambros P, Munzer C, Pearson AD, Garaventa A, Brock P, Castel V, Valteau-Couanet D, Holmes K, Di Cataldo A, Brichard B, Mosseri V, Marquez C, Plantaz D, Boni L, Michon J. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol. 2011;29:449–55.CrossRefGoogle Scholar
  34. 34.
    Owens C, Irwin M. Neuroblastoma: the impact of biology and cooperation leading to personalized treatments. Crit Rev Clin Lab Sci. 2012;49:85–115.CrossRefGoogle Scholar
  35. 35.
    Holgersen LO, Subramanian S, Kirpekar M, Mootabar H, Marcus JR. Spontaneous resolution of antenatally diagnosed adrenal masses. J Pediatr Surg. 1996;31:153–5.CrossRefGoogle Scholar
  36. 36.
    Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK, Children’s Oncology Group. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010;363:1313–23.CrossRefGoogle Scholar
  37. 37.
    De Bernardi B, Gerrard M, Boni L, Rubie H, Cañete A, Di Cataldo A, Castel V, Forjaz de Lacerda A, Ladenstein R, Ruud E, Brichard B, Couturier J, Ellershaw C, Munzer C, Bruzzi P, Michon J, Pearson AD. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol. 2009;27:1034–40.CrossRefGoogle Scholar
  38. 38.
    D’Angio GJ, Evans AE, Koop CE. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet. 1971;1:1046–9.CrossRefGoogle Scholar
  39. 39.
    Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, Atkinson JB, Selch M, Gerbing RB, Stram DO, Lukens J. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children’s Cancer Group study. J Clin Oncol. 2000;18:477–86.CrossRefGoogle Scholar
  40. 40.
    Moppett J, Haddadin I, Foot AB. Neonatal neuroblastoma. Arch Dis Child Fetal Neonatal Ed. 1999;81:F134–7.CrossRefGoogle Scholar
  41. 41.
    Hsu LL, Evans AE, D’Angio GJ. Hepatomegaly in neuroblastoma stage 4s: criteria for treatment of the vulnerable neonate. Med Pediatr Oncol. 1996;27:521–8.CrossRefGoogle Scholar
  42. 42.
    Canete A, Gerrard M, Rubie H, Castel V, Di Cataldo A, Munzer C, Ladenstein R, Brichard B, Bermúdez JD, Couturier J, de Bernardi B, Pearson AJ, Michon J. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol. 2009;27:1014–9.CrossRefGoogle Scholar
  43. 43.
    Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD, INRG Task Force. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;2:298–303.CrossRefGoogle Scholar
  44. 44.
    Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK, INRG Task Force. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27:289–97.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Pediatrics, Hôpital Couple EnfantUniversity Hospital Centre of Grenoble-AlpesGrenoble CedexFrance

Personalised recommendations